Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model
Open Access
- 12 March 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (3) , e0230238
Abstract
Social withdrawal in the sub-chronic phencyclidine (PCP) rat model, a behavioral correlate of the negative symptoms of schizophrenia, results from deficits in brain endocannabinoid transmission. As cannabis intake has been shown to affect negatively the course and expression of psychosis, we tested whether the beneficial effects of endocannabinoid-mediated CB1 activation on social withdrawal in PCP-treated rats (5 mg/kg, twice daily for 7 days)also occurred after administration of Δ9-tetrahydrocannabinol (THC; 0.1, 0.3, 1.0 mg/kg, i.p.). In addition, we assessed whether THC affected two correlates of positive symptoms: 1) motor activity induced by d-amphetamine (0.5 mg/kg, i.p.), and 2) dopamine neuron population activity in the ventral tegmental area (VTA). After the motor activity test, the brains from d-amphetamine-treated animals were collected and processed for measurements of endocannabinoids and activation of Akt/GSK3β, two molecular markers involved in the pathophysiology of schizophrenia. In control rats, THC dose-dependently produced social interaction deficits and aberrant VTA dopamine neuron population activity similar to those observed in PCP-treated animals. In PCP-treated rats, only the lowest dose of THC reversed PCP-induced deficits, as well as PCP-induced elevation of the endocannabinoid anandamide (AEA) in the nucleus accumbens. Last, THC activated the Akt/GSK3β pathway dose-dependently in both control and PCP-treated animals. Taken together, these data suggest that only low doses of THC have beneficial effects on behavioral, neurochemical and electrophysiological correlates of schizophrenia symptoms. This observation may shed some light on the controversial hypothesis of marijuana use as self-medication in schizophrenic patients.Keywords
Funding Information
- National Institute of Mental Health (R01MH91130)
This publication has 95 references indexed in Scilit:
- Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia?Current Opinion in Neurobiology, 2012
- Paranoid Schizophrenia is Characterized by Increased CB1 Receptor Binding in the Dorsolateral Prefrontal CortexNeuropsychopharmacology, 2011
- The Medial Prefrontal and Orbitofrontal Cortices Differentially Regulate Dopamine System FunctionNeuropsychopharmacology, 2011
- Unique inhibitory synapse with particularly rich endocannabinoid signaling machinery on pyramidal neurons in basal amygdaloid nucleusProceedings of the National Academy of Sciences, 2011
- Cannabis use disorders in schizophrenia: Effects on cognition and symptomsSchizophrenia Research, 2010
- Cannabinoid CB1 Receptor Immunoreactivity in the Prefrontal Cortex: Comparison of Schizophrenia and Major Depressive DisorderNeuropsychopharmacology, 2010
- Gestational methylazoxymethanol acetate administration: A developmental disruption model of schizophreniaBehavioural Brain Research, 2009
- Psychiatric Comorbidities and SchizophreniaSchizophrenia Bulletin, 2008
- Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in SchizophreniaArchives of General Psychiatry, 2008
- Iowa Gambling Task in schizophrenia: A review and new data in patients with schizophrenia and co-occurring cannabis use disordersSchizophrenia Research, 2007